Continuing vs. Withholding Home Beta-Blockers at Admission for Suspected Infection: A Target Trial Emulation
Main findingResult — go to the resultHazard ratio 0.77 95% CI 0.61–0.98Authors' conclusion
Continuation of chronic beta-blockers in a broad population of patients admitted with suspected infection was associated with improved clinical outcomes.
Study context
- Population
- Adults (≥18 y) on beta-blockers before admission, hospitalised from the ED for suspected infection (blood cultures and broad-spectrum antibiotics ordered), excluding shock, heart rate <40 or >120, or need for IV beta- or calcium channel blocker; single academic tertiary ED, Midwest USeligible
- Participants
- 4,635 adults
- Exposure
- Continuation vs No continuation
- Continuationn = 1,172
- No continuationn = 3,463reference
Methodological detailstarget trial emulation, inverse probability of treatment weighting, single-centre
- Target trial emulation
- Inverse probability of treatment weighting
- Single-centre
Main finding
As reported in the abstract
Hazard ratio
0.77
95% CI 0.61–0.98
P = 0.03
Continuation vs No continuation
HR 0.77 (95% CI 0.61–0.98); P = 0.03
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value | |
|---|---|---|---|
| Hospital LOS | IRR 0.39 (95% CI 0.38–0.41) | P < 0.001 | |
| In-hospital mortality | OR 0.60 (95% CI 0.30–1.20) | P = 0.15 | |
| 0.20.5125Ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Continuing vs. Withholding Home Beta-Blockers at Admission for Suspected Infection: A Target Trial Emulation. Crit Care Med. Published 9 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →